An Extracellular miRNA‐Responsive Artificial Receptor via Dynamic DNA Nano‐assembly for Biomarker‐Driven Therapy
Angewandte Chemie International Edition · 2023
DOI: 10.1002/anie.202305227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2023. Verfasst von Fang He und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Hunan Provincial Key La…. Hauptthemen laut MEDLINE: MicroRNAs, Receptors, Artificial, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Key Technologies Research and Development Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
MicroRNAs (miRNAs) have emerged as promising diagnostic biomarkers and therapeutic targets in various diseases. However, there is currently a lack of molecular strategies that can effectively use disease‐associated extracellular miRNAs as input signals to drive therapeutic functions. Herein, we present a modular and programmable miRNA‐responsive chimeric DNA receptor (miRNA‐CDR) capable of biomarker‐driven therapy. By grafting a miRNA‐responsive DNA nanodevice on a natural membrane receptor via aptamer anchoring, miRNA‐CDR can sense extracellular miRNA levels and autonomously induce dimerization‐mediated receptor activation via the complementary‐mediated strand displacement reaction‐induced dynamic DNA assembly. The sequence programmability of miRNA‐CDR allows it to sense and respond to a user‐defined miRNA with tunable sensitivity. Moreover, the miRNA‐CDR is versatile and customizable to reprogram desirable signaling output via adapting a designated receptor, such as MET and FGFR1. Using a mouse model of drug‐induced acute liver injury (DILI), we demonstrate the functionality of a designer miRNA‐CDR in rewiring the recognition of the DILI‐elevated miR‐122 to promote MET signaling of hepatocytes for biomarker‐driven in situ repair and liver function restoration. Our synthetic miRNA‐CDR platform provides a novel molecular device enabling biomarker‐driven therapeutic cellular response, potentially paving the way for improving the precision of cell therapy in regenerative medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Hunan Provincial Key Laboratory of Biomacromolecular Chemical Biology, Hunan University, Chan…
ORCID-Profile: Fang He, Meixia Wang, Jieyu Wang, Hong-Hui Wang, Zhou Nie
Förderung
- Key Technologies Research and Development Program
- National Natural Science Foundation of China
Zitieren
APA
He, F., Wang, M., Wang, J., Wang, H. H., & Nie, Z. (2023). An Extracellular miRNA‐Responsive Artificial Receptor via Dynamic DNA Nano‐assembly for Biomarker‐Driven Therapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202305227
Vancouver
He F, Wang M, Wang J, Wang HH, Nie Z. An Extracellular miRNA‐Responsive Artificial Receptor via Dynamic DNA Nano‐assembly for Biomarker‐Driven Therapy. Angewandte Chemie International Edition. 2023. doi:10.1002/anie.202305227
BibTeX
@article{He2023,
author = {He, Fang and Wang, Meixia and Wang, Jieyu and Wang, Hong-Hui and Nie, Zhou},
title = {An Extracellular miRNA‐Responsive Artificial Receptor via Dynamic DNA Nano‐assembly for Biomarker‐Driven Therapy},
journal = {Angewandte Chemie International Edition},
year = {2023},
doi = {10.1002/anie.202305227}
}
EUVIMED